Salvage Treatment for Locally Recurrent Nasopharyngeal Carcinoma (NPC)

被引:20
作者
Chen, Chuangzhen [1 ]
Fee, Willard [2 ]
Chen, Jianzhou [1 ]
Chan, Cato [3 ]
Khong, Brian [3 ]
Hara, Wendy [3 ]
Goffinet, Don [3 ]
Li, Derui [1 ]
Quynh-Thu Le [3 ]
机构
[1] Shantou Univ, Coll Med, Canc Hosp, Dept Radiat Oncol, Shantou, Peoples R China
[2] Stanford Univ, Dept Otolaryngol, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2014年 / 37卷 / 04期
关键词
nasopharyngeal carcinoma; recurrence; radiotherapy; surgery; outcome; PROGNOSTIC-FACTORS; STEREOTACTIC RADIOSURGERY; PHASE-II; 1ST-LINE CHEMOTHERAPY; REIRRADIATION; SURGERY; CISPLATIN; EXPERIENCE; SURVIVAL; RADIOTHERAPY;
D O I
10.1097/COC.0b013e318277d804
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: It is important to determine the outcomes of retreatment in patients with locally recurrent nasopharyngeal carcinoma. Methods: We reviewed the records of patients treated for local recurrence at Stanford and Shantou Universities. The end points were local relapse-free survival (LRFS) and overall survival after retreatment. Results: Fifty-six patients from Stanford and 98 from Shantou qualified. For the Stanford patients, 33 had surgery alone (S group), 12 had surgery plus radiotherapy +/- chemotherapy (CMT group), and 22 had radiotherapy chemotherapy (RT Stanford group). All Shantou patients received radiotherapy +/- chemotherapy (RT Shantou group). The 5-year LRFS rates were: 57% for S group, 25% for CMT group, 53% for RT Stanford group, and 41% for RT Shantou group (P > 0.05) for rT1-2 tumors; they were 29% for S group, 25% for CMT group, 39% for RT Stanford group, and 9% for RT Shantou group for rT3-4 tumors (P > 0.05). For RT patients, 5-year overall survival rates were 49% for Stanford and 25% for Shantou patients (P = 0.026). Conclusions: Similar and durable LRFS rates were attained for both S and RT groups when stratified by rT-stage.
引用
收藏
页码:327 / 331
页数:5
相关论文
共 37 条
  • [1] Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy
    Altundag, K
    Aksoy, S
    Gullu, I
    Altundag, O
    Ozyar, E
    Yalcin, S
    Cengiz, M
    Akyol, F
    [J]. MEDICAL ONCOLOGY, 2004, 21 (03) : 211 - 215
  • [2] Salvage nasopharyngectomy for radiation recurrences
    Bridger, GP
    Smee, R
    Baldwin, MAR
    Bridger, AG
    [J]. ANZ JOURNAL OF SURGERY, 2005, 75 (12) : 1065 - 1069
  • [3] Chan YW, 2011, CANCER, V118, P3710
  • [4] Locally recurrent nasopharyngeal carcinoma
    Chang, JTC
    See, LC
    Liao, CT
    Ng, SH
    Wang, CH
    Chen, IH
    Tsang, NM
    Tseng, CK
    Tang, SG
    Hong, JH
    [J]. RADIOTHERAPY AND ONCOLOGY, 2000, 54 (02) : 135 - 142
  • [5] Salvage surgery for locally recurrent nasopharyngeal carcinoma - A 10-year experience
    Chang, KP
    Hao, SP
    Tsang, NM
    Ueng, SH
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2004, 131 (04) : 497 - 502
  • [6] Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis
    Chua, Daniel T. T.
    Wu, Shao-Xiong
    Lee, Victor
    Tsang, Janice
    [J]. HEAD & NECK ONCOLOGY, 2009, 1 : 13
  • [7] A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma
    Chua, DTT
    Sham, JST
    Au, GKH
    [J]. ORAL ONCOLOGY, 2005, 41 (06) : 589 - 595
  • [8] Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: Efficacy and complications
    Chua, DTT
    Sham, JST
    Kwong, PWK
    Hung, KN
    Leung, LHT
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 177 - 183
  • [9] Salvage surgery for recurrent nasopharyngeal carcinoma
    Danesi, Giovanni
    Zanoletti, Elisabetta
    Mazzoni, Antonio
    [J]. SKULL BASE-AN INTERDISCIPLINARY APPROACH, 2007, 17 (03): : 173 - 180
  • [10] Fee WE, 2002, ARCH OTOLARYNGOL, V128, P280